INAB

IN8bio, Inc.

0.88 USD
-0.01 (-0.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

IN8bio, Inc. stock is down -15.18% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 June’s closed higher than May. 100% of analysts rate it a buy.

About IN8bio, Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, which is in Phase I clinical trial for glioblastoma and solid tumors. InB-100, an allogeneic product candidate, is in clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation.

  • Jones Trading
    Fri Jun 14, 10:55
    buy
    confirm
  • HC Wainwright & Co.
    Fri Jun 14, 06:21
    buy
    confirm
  • HC Wainwright & Co.
    Tue Jun 4, 07:05
    buy
    confirm